These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34017938)

  • 1. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares.
    Gupta PK; Venkateswaran N
    Ther Adv Ophthalmol; 2021; 13():25158414211012797. PubMed ID: 34017938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease.
    Venkateswaran N; Bian Y; Gupta PK
    Clin Ophthalmol; 2022; 16():349-355. PubMed ID: 35173413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease.
    Paton DM
    Drugs Today (Barc); 2022 Feb; 58(2):77-84. PubMed ID: 35188142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KPI-121 1% for pain and inflammation in ocular surgery.
    Beckman KA; Katz JA; Majmudar PA; Rips AG; Vaidya NS; Rostov AT
    Pain Manag; 2022 Jan; 12(1):17-23. PubMed ID: 34164994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
    Schopf L; Enlow E; Popov A; Bourassa J; Chen H
    Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies.
    Korenfeld M; Nichols KK; Goldberg D; Evans D; Sall K; Foulks G; Coultas S; Brazzell K
    Cornea; 2021 May; 40(5):564-570. PubMed ID: 32826644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
    Beckman K; Katz J; Majmudar P; Rostov A
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of corneal nerve density on the response to treatment in dry eye disease.
    Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
    Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quintessence of currently approved and upcoming treatments for dry eye disease.
    Patil S; Sawale G; Ghuge S; Sathaye S
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; ():. PubMed ID: 39215848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loteprednol etabonate: clinical potential in the management of ocular inflammation.
    Noble S; Goa KL
    BioDrugs; 1998 Oct; 10(4):329-39. PubMed ID: 18020605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery.
    Lyseng-Williamson KA
    Drugs; 2013 Jun; 73(9):949-58. PubMed ID: 23740411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery.
    Kim T; Sall K; Holland EJ; Brazzell RK; Coultas S; Gupta PK
    Clin Ophthalmol; 2019; 13():69-86. PubMed ID: 30643381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye.
    Hovanesian JA; Keyser A; Berdy G; Sorensen R
    Clin Ophthalmol; 2022; 16():3841-3849. PubMed ID: 36438591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery.
    Kang C; Keam SJ; Shirley M; Syed YY
    Clin Drug Investig; 2020 Apr; 40(4):387-394. PubMed ID: 32172521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the treatment of dry eye with Loteprednol Etabonate].
    Wan PX; Wang XR; Song YY; Li ZY; Duan HC; Zhang W; Liu Z; Wang ZC
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):142-7. PubMed ID: 22490950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucus-Penetrating Particles and the Role of Ocular Mucus as a Barrier to Micro- and Nanosuspensions.
    Popov A
    J Ocul Pharmacol Ther; 2020; 36(6):366-375. PubMed ID: 32667250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
    Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a role for tapered topical dose steroidal treatment for dry eye disease? A randomized, pilot study.
    Barabino S; Montaldo E; Mingari MC; Mazzotta C; Giuffrida S; Rolando M
    Eur J Ophthalmol; 2022 Jul; 32(4):2452-2458. PubMed ID: 34585595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.